181 related articles for article (PubMed ID: 28872911)
21. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Yoshino H; Kimura A
Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563
[TBL] [Abstract][Full Text] [Related]
23. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
Noto Y; Shibuya K; Vucic S; Kiernan MC
Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
[TBL] [Abstract][Full Text] [Related]
24. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
Park JM; Kim SY; Park D; Park JS
Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
[TBL] [Abstract][Full Text] [Related]
25. Edaravone: A new drug approved for ALS.
Rothstein JD
Cell; 2017 Nov; 171(4):725. PubMed ID: 29100067
[TBL] [Abstract][Full Text] [Related]
26. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
[TBL] [Abstract][Full Text] [Related]
27. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
Aoki M; Warita H; Mizuno H; Suzuki N; Yuki S; Itoyama Y
Brain Res; 2011 Mar; 1382():321-5. PubMed ID: 21276427
[TBL] [Abstract][Full Text] [Related]
28. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
[TBL] [Abstract][Full Text] [Related]
29. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
[TBL] [Abstract][Full Text] [Related]
30. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Tomar S; Gupta S; Singal A; Soni R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
[TBL] [Abstract][Full Text] [Related]
32. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.
Ito H; Wate R; Zhang J; Ohnishi S; Kaneko S; Ito H; Nakano S; Kusaka H
Exp Neurol; 2008 Oct; 213(2):448-55. PubMed ID: 18718468
[TBL] [Abstract][Full Text] [Related]
33. Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature.
Ren Y; Wei B; Song X; An N; Zhou Y; Jin X; Zhang Y
Int J Neurosci; 2015; 125(8):555-65. PubMed ID: 25171224
[TBL] [Abstract][Full Text] [Related]
34. In brief: Edaravone oral suspension (Radicava ORS) for ALS.
Med Lett Drugs Ther; 2022 Sep; 64(1658):e1. PubMed ID: 36098666
[No Abstract] [Full Text] [Related]
35. Edaravone for treatment of early-stage ALS.
Mora JS
Lancet Neurol; 2017 Oct; 16(10):772. PubMed ID: 28920880
[No Abstract] [Full Text] [Related]
36. Edaravone: a new treatment for ALS on the horizon?
Hardiman O; van den Berg LH
Lancet Neurol; 2017 Jul; 16(7):490-491. PubMed ID: 28522180
[No Abstract] [Full Text] [Related]
37. Edaravone for treatment of early-stage ALS - Authors' reply.
Akimoto M; Nakamura K;
Lancet Neurol; 2017 Oct; 16(10):772. PubMed ID: 28920878
[No Abstract] [Full Text] [Related]
38. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
Ismail II; Massoud F; Kamel WA; Al-Hashel JY
Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
[TBL] [Abstract][Full Text] [Related]
39. Edaravone Mitsubishi-Tokyo.
Tabrizchi R
Curr Opin Investig Drugs; 2000 Nov; 1(3):347-54. PubMed ID: 11249718
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Nourelden AZ; Kamal I; Hagrass AI; Tawfik AG; Elhady MM; Fathallah AH; Eshag MME; Zaazouee MS
Neurol Sci; 2023 Oct; 44(10):3429-3442. PubMed ID: 37249667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
